Clinical trials: Tumor of Prostate
Prostate Cancer
Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations
This clinical utility study pilot is based on a review of real but de-identified and randomized patient cases and aims to evaluate Urologists' treatment recommendations before and after reviewing the results provided by the…
- Trial name
- DECIDE (NCT02020876)
- Testing
- DECIPHER Questionnaire
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GenomeDx Biosciences Corp
Metastatic Castration Resistant Prostate Cancer
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined…
- Trial name
- PREMISE (NCT02495974)
- Testing
- enzalutamide
- Where
- 182 sites in Austria, Belgium and 14 more
- Volunteers
- 1,763 people
- Sponsor
- Astellas Pharma Europe Ltd.
Localised Prostate Cancer
BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer
The goal of this randomised clinical trial is to assess whether personalised treatment counselling can improve the decision-making experience in patients with a new diagnosis of localised prostate cancer.
- Trial name
- BeSpoke (NCT07135271)
- Testing
- Bespoke Decision Support tool, Standard of Care (SOC) decision support material
- Where
- United Kingdom
- Volunteers
- 346 people
- Sponsor
- University College, London
Prostate Cancer
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
This is the first study of MLN2704 administered to humans. The purpose of the study is to determine the highest dose of MLN2704 that can be given safely to patients with prostate cancer, and to identify any side effects…
- Trial name
- NCT00052000
- Testing
- MLN2704 (DM1 conjugated monoclonal antibody MLN591)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating…
- Trial name
- NCT00003607
- Testing
- radiation therapy
- Where
- 23 sites in France
- Volunteers
- 450 people
- Sponsor
- UNICANCER
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
This randomized pilot clinical trial studies intensive diet and exercise or standard of care in improving physical function and quality of life in patients with prostate cancer undergoing androgen deprivation therapy.
- Trial name
- IDEA-P (NCT02050906)
- Testing
- behavioral dietary intervention, exercise intervention, behavioral activity counseling
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Decision Making, Shared, Prostate-Specific Antigen
Promoting Shared-decision Making in Opportunistic Screening for Prostate Cancer
In this project, the investigators aim to evaluate the most appropriate design and implementation strategy of a decision-aid to promote shared-decision making in prostate cancer screening.
- Conditions
- Decision Making, Shared, Prostate-Specific Antigen, Prostate Cancer
- Trial name
- PROSHADE (NCT05187949)
- Testing
- Mixed-method approach
- Volunteers
- 1,781 people, healthy volunteers welcome
- Sponsor
- Universidad Miguel Hernandez de Elche
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Glioblastoma, Squamous Cell Carcinoma
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO.
- Conditions
- Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
- Trial name
- NCT05974410
- Testing
- AVM0703, Hydrocortisone, Proton pump inhibitor
- Sponsor
- AVM Biotechnology Inc
Prostate Cancer
Long-term Better Than Short-term ADT With Salvage RT
A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after…
- Trial name
- LOBSTER (NCT04242017)
- Testing
- Triptoreline
- Where
- 3 sites in Belgium
- Volunteers
- 394 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Prostate Cancer
Selenium in Preventing Prostate Cancer
RATIONALE: Selenium supplements may stop or delay the development of prostate cancer in patients at high risk of prostate cancer. It is not yet known which dose of selenium may be more effective in preventing prostate cancer.
- Trial name
- NCT00978718
- Testing
- high-selenium baker's yeast, selenium
- Volunteers
- 700 people
- Sponsor
- University of Arizona
Prostate Cancer
Testosterone in Castration-Resistant Prostate Cancer
Primary Objective: 1. To assess the prostate-specific antigen (PSA)-response (50% decline) to Testosterone Replacement Therapy (TRT) in men with "intermediate and good-risk" Castration-Resistant Prostate Cancer (CRPC).
- Trial name
- NCT00577980
- Testing
- Testosterone
- Sponsor
- M.D. Anderson Cancer Center
Health Status Unknown, Prostate Carcinoma
Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer
This pilot clinical trial studies transrectal magnetic resonance imaging (MRI)-guided biopsy to see how well it works in identifying cancer in patients with suspected prostate cancer who are scheduled to undergo standard biopsy.
- Trial name
- NCT02501759
- Testing
- 3 Tesla Magnetic Resonance Imaging, Gadodiamide, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostatic Neoplasm
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide in patients with hormone-refractory prostate cancer.
- Trial name
- NCT00001446
- Testing
- thalidomide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back (recurrent)…
- Trial name
- NCT02940262
- Testing
- Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 1,138 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases
The objective of this trial is to assess the value of 18F-choline PET/CT for the detection of regional lymph node metastases from prostate cancer.
- Trial name
- PROPET (NCT00670527)
- Testing
- [18F] Fluorocholine PET/CT
- Where
- Denmark
- Volunteers
- 205 people
- Sponsor
- Odense University Hospital
Prostate Cancer
Aberrant Gene Expression Prostate Carcinoma
The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and…
- Trial name
- NCT00868803
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Lahey Clinic